Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study. - Wikidata - wikimedia - TriplyDB

Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study.

Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study.

http://www.wikidata.org/entity/Q37364364

about

Antibodies to watch in 2015 Neuroblastoma after childhood: prognostic relevance of segmental chromosome aberrations, ATRX protein status, and immune cell infiltration GD2-targeted immunotherapy and radioimmunotherapy Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibody.Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma.Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2 Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells.Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot.A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials.Charge heterogeneity: Basic antibody charge variants with increased binding to Fc receptors.IL-10 and ARG-1 concentrations in bone marrow and peripheral blood of metastatic neuroblastoma patients do not associate with clinical outcome.Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival.Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials.Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.Anti-GD2 immunotherapy for neuroblastoma.Immunohistochemical evaluation of molecular radiotherapy target expression in neuroblastoma tissue.Cell death-based treatment of neuroblastoma.Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO.PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO.Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial

P2860

Q28253501-C47B8554-C213-4215-9CF9-B04758828C05 Q34346730-20D812EA-5BC9-48B8-98B4-A4E5969FA5E4 Q34625339-82AEB59F-96EB-4F1C-991C-C4EC1F922316 Q35255233-BD6D1BDA-05F0-4D07-BA26-FCD0108178B8 Q35953824-21642D4F-5EC1-475B-92C0-D1F3DBA59149 Q37139002-C3F96B69-D574-4FAC-9A4E-FBDAB1DFF9B2 Q37725488-D96A3E22-5EEF-4BA1-B92F-2DAE6258D6D0 Q38643300-883E12E7-8F95-4731-8A9D-128B861790C7 Q38961012-BF19AC19-3977-449E-8795-F65BB7220982 Q39454978-DAFEF330-B5A5-416B-8C7F-CFCB40E7495F Q40190430-BAC0FB7B-C1B1-4DA7-9FC1-704D7C91B306 Q41689901-64BD9FC8-9611-43C5-9783-0A89C491BFEE Q44123857-9C9E081C-A955-474F-8121-5B7F22C3AC81 Q47176287-E1EF7094-395A-48E1-B833-8CF2929E2AB5 Q47554435-B6410E5C-A2B8-4F93-8681-3E6E3A8DBCF0 Q47771714-3CDE69DF-486F-4475-8679-A5A5C13E58DF Q47839039-0A03691F-4303-4EF1-9318-AB5807E97962 Q49888224-AA31C395-BDD8-4D50-A815-82E6492FB5BA Q50445794-FA3D43EC-3AE1-4832-A6C2-A8170E4DFB5E Q58605647-23384782-4B45-4E1C-B9D5-3EA09F975EE3

P2860

Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study.

http://www.wikidata.org/entity/Q37364364

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 31 May 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Ch14.18 antibody produced in C ...... ients: a SIOPEN Phase 1 study.

@en

Ch14.18 antibody produced in C ...... ients: a SIOPEN Phase 1 study.

@nl

type

label

Ch14.18 antibody produced in C ...... ients: a SIOPEN Phase 1 study.

@en

Ch14.18 antibody produced in C ...... ients: a SIOPEN Phase 1 study.

@nl

prefLabel

Ch14.18 antibody produced in C ...... ients: a SIOPEN Phase 1 study.

@en

Ch14.18 antibody produced in C ...... ients: a SIOPEN Phase 1 study.

@nl

P1433

Q37364364-4D9C4C72-9EDF-4ECA-8CB4-2D293A556DBC

P1476

Q37364364-A66EF50C-B56A-4F21-BD19-B34AC5778875

P2093

Q37364364-281169C8-8FFF-47B3-82A2-F06C9DEEF006

Q37364364-562885CA-93B2-4D3D-8D99-BEDFB75235C3

Q37364364-56F53AB2-6C2C-4617-A9BB-385ECE0E2331

Q37364364-7442EDCD-4559-4B9E-8514-3209DBC145DA

Q37364364-92991BE9-012A-4D7C-8C3C-3CC83B6A9A8C

Q37364364-B5684258-49E9-4F4D-B0D7-00180304C569

Q37364364-C5928117-49B4-41A0-A39B-175344A1F181

Q37364364-DACC0836-72C7-440B-9E8D-9CDE91584D6B

Q37364364-DF80AD78-D611-42EB-9CE5-89B863199B0B

Q37364364-ED6224EA-AEBE-4352-BF95-7C005758114F

P2860

Q37364364-29428227-9D9E-4EC2-A415-EE87F446D2AC

Q37364364-38D76F3A-E03C-470C-BD64-612BD68158A9

Q37364364-4EDA7FA4-13C5-48C7-92AB-F7B6CEA3DA46

Q37364364-534254E1-364D-4AAD-B384-9BA137FF561C

Q37364364-8438ECD4-5172-4C7D-9FF2-649EB86DB6AB

Q37364364-8977C4F0-393B-4C08-997B-C7C12F0D6E06

Q37364364-93D7ECF2-60CE-4800-8A30-E4B5761C8C43

Q37364364-950FB9DE-8A1C-4F3C-B396-4EF1DF1828FA

Q37364364-9C0DAF73-E458-471E-9C78-BF16A2DD78D2

Q37364364-9E87219A-FF7F-45E7-9FE7-EB186E10B29C

P304

Q37364364-C7C0576F-F42B-4D21-9449-19C0D35B0E30

P31

Q37364364-ADFBCD28-1C31-41AC-B689-E5D1816DF46C

P356

Q37364364-C086AF3A-44AA-4B54-BBD5-D5F45F0EAAA3

P433

Q37364364-5532DE39-157E-4CE4-86FB-A1826F98456D

P478

Q37364364-6793C485-BB3A-4FFC-8A6B-09697E28D151

P50

Q37364364-06D215E9-7390-474A-A820-AE42C69CDF97

Q37364364-DF9D6A3C-B2AE-45F7-BC60-5ED9D08992CD

Q37364364-EE49EBCD-0F8B-41FB-AEB8-9C803A6B0943

P577

Q37364364-9E9D0A2F-58A0-4FE1-A63E-503C8C1C7959

P5875

Q37364364-CCFF1004-A69F-4C13-B532-C0BB3636AE7D

P698

Q37364364-845E75A8-94DF-4F23-B1A8-C70A8812180D

P921

Q37364364-7DC2AB9A-B097-4EC4-AECD-F14DC4DF6C02

P932

Q37364364-E85CE214-5A4D-48F1-B446-A44E0FDD169F

P356

P1433

Monoclonal Antibodies

P1476

Ch14.18 antibody produced in C ...... tients: a SIOPEN Phase 1 study

@en

P2093

Bianca Baykan

http://www.w3.org/2001/XMLSchema#string

Dietmar Katinger

http://www.w3.org/2001/XMLSchema#string

Ingrid Pribill

http://www.w3.org/2001/XMLSchema#string

Jean Michon

http://www.w3.org/2001/XMLSchema#string

Matthias Bleeke

http://www.w3.org/2001/XMLSchema#string

Petra Glander

http://www.w3.org/2001/XMLSchema#string

Ruth Ladenstein

http://www.w3.org/2001/XMLSchema#string

Silke Weixler

http://www.w3.org/2001/XMLSchema#string

Steffen Bauer

http://www.w3.org/2001/XMLSchema#string

Vito Pistoia

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.

Novel mechanism for the generation of human xeno-autoantibodies against the nonhuman sialic acid N-glycolylneuraminic acid.

Monoclonal antibodies: versatile platforms for cancer immunotherapy.

Anti-GD2 Strategy in the Treatment of Neuroblastoma

Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma.

Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy.

Antibody-based immunotherapy in high-risk neuroblastoma.

Vaccination with anti-idiotype antibody ganglidiomab mediates a GD(2)-specific anti-neuroblastoma immune response.

P304

801-809

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/MABS.25215

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Alberto Garaventa

P577

2013-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

255706204

http://www.w3.org/2001/XMLSchema#string

P698

23924804

http://www.w3.org/2001/XMLSchema#string

P921

P932

3851232

http://www.w3.org/2001/XMLSchema#string